P L A I N L A N G U A G E S U M M A R Y
Nebulised (with or without oral) antibiotics for early infection with Pseudomonas aeruginosa in cystic fibrosis, may eradicate the organism and delay chronic infection Cystic fibrosis blocks the airways with mucus and causes frequent respiratory infections, which may lead to death from breathing failure. A germ called Pseudomonas aeruginosa is a frequent cause of infection. We found that nebulised antibiotics (or a combination of nebulised and oral antibiotics) were better than no treatment in treating early infection with this germ, which was eliminated in the majority of individuals. The trials had a relatively short follow-up period and we were unable to show whether treatment made people with cystic fibrosis feel better or live longer. Further research is needed to see whether eradication improves welbeing and quality of life in people with CF.
B A C K G R O U N D
Cystic fibrosis (CF) is the most common life-limiting, autosomal recessively inherited disease in Caucasian populations. Although this is a multisystem disease, the primary cause of death in CF is respiratory failure resulting from chronic pulmonary infection (FitzSimmons 1993) . Pseudomonas aeruginosa (P. aeruginosa) is the most frequent cause of chronic pulmonary infection beyond infancy in people with CF and once established appears to be permanent in the majority of cases (Fitzsimmons 1996) . The accepted definition of chronic infection with P. aeruginosa in the lower respiratory tract, which will be used in this review, is the culture of P. aeruginosa on two or more occasions over a six month period, or a shorter period if accompanied by a sustained rise in anti-pseudomonas antibodies (Brett 1992; Høiby 1974) . Other definitions have been suggested, such as the isolation of P. aeruginosa in more than 50% of monthly specimens (Lee 2003) . The age specific prevalence of P. aeruginosa in pre-school children is 9%, rising to 32% for 10 to 15 year olds (UK CF Database 2003) . Some authors have suggested that the use of prophylactic antistaphylococcal antibiotic therapy in early childhood may predispose to chronic P. aeruginosa infection (Ratjen 2001b; Stutman 2002) . However, this effect was not seen in a systematic review of prophylactic antibiotic use, including over 400 participants (Smyth 2003) .
In children who are too young to expectorate, cough swabs or oropharyngeal swabs are the only respiratory specimens which can be easily obtained. These do not reliably predict the presence of P. aeruginosa in the lower respiratory tract (Armstrong 1996; Rosenfeld 1999) , whereas sputum cultures have been shown to accurately reflect lower respiratory tract organisms in expectorating children and adults (Iacocca 1963; Thomassen 1984) . Most people with CF have chronic infection with P. aeruginosa by early adulthood (Döring 2000) although prior to chronic infection, P. aeruginosa is often isolated intermittently from lower respiratory tract specimens. This may represent transient colonies of P. aeruginosa within the lower respiratory tract or alternatively it may reflect the difficulties in accurately detecting P. aeruginosa in the lungs of young people with CF (Burns 2001) .The quantity and type of P. aeruginosa present in the lower respiratory tract changes as infection becomes established. P. aeruginosa has two major strains -mucoid and non-mucoid. Following first isolation there is a progressive increase in the density of P. aeruginosa colonies in the lower respiratory tract (Rosenfeld 2001) . Initial isolates are often non-mucoid strains, however as infection progresses mucoid strains prevail. P. aeruginosa provokes an inflammatory response of the lower respiratory tract (Muhlebach 1999) and there is a marked step up in this inflammatory response as the number of P. aeruginosa colonies increases (Armstrong 1996) .
The presence of P. aeruginosa in respiratory secretions is a major predictor of mortality in children with CF (Emerson 2002) . Individuals with CF infected with P. aeruginosa also suffer greater morbidity with a more rapid deterioration in lung function (Emerson 2002; Pamukcu 1995) and a more rapid decline in chest radiograph score (Kosorok 2001) , poor growth, reduced quality of life, increased hospitalisation and increased need for antibiotic treatment (Ballmann 1998; Nixon 2001; Winnie 1991) . Some trials suggest there is a temporal relationship between the onset of chronic infection and increased morbidity (Abman 1991; Hudson 1993; Kosorok 2001; Parad 1999) , whilst others do not support these findings (Kerem 1990; Rosenfeld 2001) . On balance, there seems to be good evidence from well-designed non-experimental studies that clinical state deteriorates after first isolation of P. aeruginosa.
It has been suggested that antibiotic treatment against P. aeruginosa given at the time of first isolation may prevent or delay chronic infection (Frederiksen 1997) . Other strategies which have the potential to prevent or delay infection of the lower respiratory tract with P. aeruginosa include avoidance of contact with people who carry P. aeruginosa (UK CF Trust 2004) and the development of vaccines against P. aeruginosa (Keogan 2002). Uncontrolled series have indicated that a variety of anti-pseudomonal antibiotics either singly (Littlewood 1985; Ratjen 2001a ) or in combination (Vazquez 1993 at first isolation may delay the onset of chronic infection. A trial using historical controls suggested that oral ciprofloxacin and nebulised colistin are effective in delaying or preventing chronic infection (Frederiksen 1997 ). An uncontrolled pilot study of intravenous therapy suggested that intravenous treatment alone was less effective in delaying the onset of chronic infection (Steinkamp 1989) . There is also evidence supporting eradication therapy from long-term observational studies of chronic infection with P. aeruginosa in CF clinics such as the study reported by Lee (Lee 2004).
There are differences in the approach to detection and management of first isolation of P. aeruginosa. Some CF centres advocate frequent microbiological surveillance with attempts to eradicate P. aeruginosa when it first appears in the lung (Döring 2000) whereas others treat only when clinical or radiological signs of pulmonary infection are present (Ramsey 1996) . There is evidence that, when P. aeruginosa is cleared from respiratory secretions it is not simply suppressed because, when infection recurs, this is with a genetically distinct organism in most cases (Munck 2001) . It is uncertain whether eradication strategies result in increased survival or improved quality of life for CF sufferers. The cost-effectiveness of these strategies remains undetermined.
O B J E C T I V E S
To determine whether antibiotic treatment of early P. aeruginosa infection in children and adults with CF alters clinical and microbiological outcome when compared to usual treatment.
To test the hypotheses that antibiotics against P. aeruginosa, given at the time of first isolation, reduces CF-related mortality; improves quality of life; improves pulmonary function; nutritional status; and reduces the need for subsequent hospitalisation and consumption of antibiotics. To investigate whether these antibiotics prevent or delay the onset of chronic infection of the lower respiratory tract with P. aeruginosa; increase the incidence of isolates of other micro-organisms from the lower respiratory tract; and are associated with adverse effects which are either important to the individual with CF or have long-term sequelae.
C R I T E R I A F O R C O N S I D E R I N G S T U D I E S F O R T H I S R E V I E W

Types of studies
Randomised controlled trials.
Types of participants
Children and adults with CF, diagnosed clinically and by sweat or genetic testing (or both) with a first positive microbiological isolate of P. aeruginosa from a lower respiratory tract specimen. Participants should be enrolled into a trial within two months from first isolation of P. aeruginosa. People with CF of all ages and disease severity will be included, however participants with evidence of past P. aeruginosa isolation or raised specific antibody titres to P. aeruginosa will be excluded from analysis.
Types of intervention
Combinations of inhaled, oral or intravenous antibiotics with the aim of eradicating first pulmonary isolates of P. aeruginosa compared with placebo or usual treatment (or both) or other combinations of inhaled, oral or intravenous antibiotics.
Types of outcome measures
Primary outcomes
(1) Eradication of P. aeruginosa from the lower respiratory tract as defined by: (a) no isolation of P. aeruginosa from bronchoalveolar lavage (BAL), sputum or oropharyngeal cultures at 1, 2, 3, 6,12 and 24 months after commencement of therapy; (b) time to next isolation of P. aeruginosa from BAL, sputum or oropharyngeal cultures. Outcome data were grouped into those measured at one, three, six, twelve months and annually thereafter. In addition, we previously stated that if outcome data were recorded at other time periods as well, that we would also consider examining these data. Data at two months for some outcomes were reported, and we have included these data within the review. 
Secondary outcomes
S E A R C H M E T H O D S F O R I D E N T I F I C A T I O N O F S T U D I E S
M E T H O D S O F T H E R E V I E W
The two authors (DW, AS) independently selected the trials to be included in the review. Each author independently assessed the methodological quality of each trial, based on the method described by Schulz (Schulz 1995). In particular, authors examined details of the randomisation method, method of allocation concealment, the degree of blinding in the trial, whether intentionto-treat analyses were possible from the available data, and if the number of participants lost to follow up, or subsequently excluded from the trial, were recorded. Each author independently extracted data using standard data acquisition forms. Where there was disagreement on the suitability of a trial for inclusion in the review, or on its quality, the authors reached a consensus by discussion.
For binary outcome measures, in order to allow an intention-totreat analysis, we sought data on the number of participants with each outcome event, by allocated treated group, irrespective of compliance and whether or not the participant was later thought to be ineligible or otherwise excluded from treatment or follow up. In trials where outcome data were unavailable for participants who had been randomised, we performed an available case analysis. This available case analysis included data on only those participants whose results are known, using as a denominator the total number of people who completed the trial for the particular outcome in question. We calculated a pooled estimate of the treatment effect for each outcome across trials, (the odds ratio or the ratio of the odds of an outcome among treatment allocated participants to the corresponding odds among controls). When data were incomplete, we imputed the missing data to provide best case and worst case scenarios, in order to show the range of possible results for the combined analysis (see graphs 01,06; 01,07; 01,08). The best case scenario analysis is based on the assumption that all the missing data points represented beneficial clinical outcomes, whereas the worst case analysis assumes that all missing data points had a negative clinical outcome.
For continuous outcomes, in order to allow an intention-to-treat analysis, we sought outcome data by allocated treated group, irrespective of compliance and whether or not the participant was later thought to be ineligible or otherwise excluded from treatment or follow up. We recorded either mean change from baseline for each group or mean post-treatment or intervention values and standard deviation. We calculated a pooled estimate of treatment effect by calculating the weighted mean difference. We have reported longitudinal data as individual time points. We realise that this method ignores any correlation between the participants; however, we have been unable to analyse these data using more appropriate methods as we do not have the correlation co-efficient for these data. If in the future, we are able to obtain the correlation co-efficient, we will analyse these data more appropriately.
For future updates of this review, for time-to-event data, such as time to next P. aeruginosa infection or time to chronic infection, we will attempt to obtain individual patient data (IPD). We will use these IPD to provide estimates of the log hazard ratio and its standard error and plan to combine time-to-event data from trials in a meta-analysis. We will assess heterogeneity using the I 2 statistic (Higgins 2003). If we find evidence of clinical heterogeneity in the included trials, we plan to perform a random effects analysis. In this version of the review, time-to-event data were not available, but binary data were presented on clearance of P. aeruginosa from BAL, sputum or oropharyngeal cultures and occurrence of chronic infection with P. aeruginosa at multiple time points. Therefore, we calculated the odds ratio (or odds of an outcome among treatment allocated participants to the corresponding odds among controls) at each time point separately, thus ignoring the correlation between time points.
Cross-over trials are not eligible for inclusion within this review. The natural history of infection with P. aeruginosa in CF comprises an initial infection with the organism in planktonic form followed by chronic infection by the P. aeruginosa biofilm. In the planktonic form, the organism can be eradicated with antibiotics. However, once a biofilm has formed, eradication is not possible. In a crossover trial, comparing active treatment with placebo, the group receiving the active treatment after placebo will therefore be at a disadvantage compared with those receiving active treatment first. The P. aeruginosa may form a biofilm during placebo treatment and so it could not be eradicated during the active treatment phase. Hence, a cross-over trial is an inappropriate design and cross-over trials have not been included in this review.
D E S C R I P T I O N O F S T U D I E S
A total of 19 trials were identified by our search. Of these trials three met our inclusion criteria (Gibson 2003; Valerius 1991; Wiesemann 1998) . These three trials were parallel in design and enrolled a total of 69 participants. No cross-over trials were identified.
The Gibson trial was a randomised, double-blind, placebo-controlled, parallel-group, multicentre trial (Gibson 2003) . There were a total of 21 participants (11 males) were included, from nine centres in North America. Participants were aged six months to six years with microbiological evidence of recent onset of persistent P. aeruginosa infection of the lower airways. Participants were randomised to receive either tobramycin solution for inhalation (TSI) (300 mg twice-daily, for 28 days at home) or to placebo inhalations. Randomisation was stratified for age and participating centre. The planned sample size was 98 participants. The randomisation was stopped early after an interim analysis by the 'Data Monitoring Committee', which was performed because of poor accrual. This analysis showed a statistically significant treatment effect. All randomised participants completed the trial. The primary outcome measure was eradication of P. aeruginosa from lower respiratory tract specimens, with oropharyngeal cultures measured at entry and on days 14, 28, 42 and 56. Bronchoscopic BAL fluid for culture was obtained from the same lobar segment on trial entry as well as day 28. Other measured outcomes included nutritional status, modified Shwachman score and monitoring for adverse clinical and microbiological effects.
The Valerius trial was a randomised, placebo-controlled, parallelgroup, single-centre trial (Valerius 1991) . There were a total of 26 participants (13 males), from one Danish CF Centre, with evidence of recent onset of persistent P. aeruginosa infection of the lower airways. Participants were randomised, without stratification, to receive either treatment with ciprofloxacin 250 mg to 750 mg (according to body weight) twice-daily and inhalation of colistin 1MU twice-daily for three weeks at entry to the trial (and each time P. aeruginosa was subsequently isolated from monthly sputum samples) or to no (standard) treatment. The end point was chronic infection with P. aeruginosa and results were expressed as time-to-chronic infection (defined as presence of P. aeruginosa in monthly sputum samples for six consecutive months or the development of precipitating serum antibodies against P. aeruginosa) or both. There were no withdrawals during the trial period.
The Wiesemann trial was a randomised, double-blind, placebocontrolled, parallel-group, multicentre trial (Wiesemann 1998). There were a total of 22 participants (9 males) from five German paediatric CF centres, aged 4 to 18 years with microbiological evidence of recent onset of persistent P. aeruginosa infection. Individuals with raised titres to anti-pseudomonal antibodies were excluded from the trial. Participants were randomised to receive either aerosolised tobramycin parenteral preparation (Eli Lilly, Bad Homburg Germany) (80 mg) or placebo containing the same preservatives to be inhaled twice-daily for 12 months. Eight participants (two from the treatment group and six from the placebo group) failed to complete the trial. These withdrawals were prompted by a variety of reasons, including: unwillingness to do daily inhalations; need for intravenous treatment; cough during inhalations; lack of the expected effect of treatment on cough and sputum production. The primary outcome was time to clearance of P. aeruginosa from the lower airways with monthly sputum or oropharyngeal swabs during the trial period Trials with no control group were excluded (Heinzl 2002; Littlewood 1985; Ratjen 2001a; Steinkamp 1989; Taccetti 2005) , as were trials which used historical controls (Frederiksen 1997; Vazquez 1993; Taccetti 2005) and those which were observational in nature (Ballmann 1998). Likewise, we excluded trials designed to evaluate a diagnostic technique for P. aeruginosa (Brett 1992; Wainwright 2002) and those which evaluated symptomatic rather than eradication treatment (Church 1997; Schaad 1997) . No cross-over trials were identified.
Fourteen trials were excluded: one trial was excluded as it was not randomised (Gibson 2007); four trials were excluded as they did not have a control group (Heinzl 2002; Littlewood 1985; Ratjen 2001a; Steinkamp 1989) ; four trials were excluded as they used historical controls (Frederiksen 1997; Griese 2002; Taccetti 2005; Vazquez 1993) ; one trial was excluded because it was an observational study (Ballmann 1998); two trials were excluded as they were designed to evaluate a diagnostic technique for P. aeruginosa (Brett 1992; Wainwright 2002) ; and two trials were excluded as they evaluated symptomatic rather than eradication treatment (Church 1997; Schaad 1997).
Two trials were identified which are still ongoing (Ramsey 2005; Ratjen 2006) . Further details of these can be found in the table 'Characteristics of ongoing studies'. Data from these trials will be included in a future update of this review once they have been published.
M E T H O D O L O G I C A L Q U A L I T Y
Methodological quality was assessed using the criteria described by Schulz (Schulz 1995). Briefly, these criteria evaluate concealment of treatment allocation schedule, generation of allocation sequence, blinding and whether analysis was by intention-to-treat.
The three trials were reported as randomised controlled trials; in two, the method of generation of allocation sequence was not stated (Gibson 2003; Valerius 1991) . In the third the allocation sequence was generated using a coin flip (Wiesemann 1998). There is no information as to who was responsible for the coin flip or what controls were in place to ensure validity of the result of the coin flip.
None of the trials reported how allocation was concealed (Gibson 2003; Valerius 1991; Wiesemann 1998) .
Two trials were reported as double blind trials (Gibson 2003; Wiesemann 1998 ). Gibson did not provide any details regarding who was blinded or the method of blinding (Gibson 2003) . Wiesemann reported that participants were blinded by providing a placebo inhalation with a similar taste to the treatment inhalation, but it is not clear whether the clinicians administering the treatment were blinded to treatment allocation (Wiesemann 1998).The remaining trial did not utilise blinding (Valerius 1991).
Two trials were analysed on an intention-to-treat basis (Gibson 2003; Valerius 1991) ; both reported data on all participants who were randomised. There were no dropouts reported in either trial. In one trial, five participants withdrew from the trial after randomisation (Wiesemann 1998). Only baseline data at entry to this trial were presented for these participants and to date we have been unable to obtain further outcome data. The trial was therefore analysed on an available case basis (Wiesemann 1998).
Please see further information in the 'Additional tables' section of the review (Table 01) .
R E S U L T S
Tobramycin (inhaled) versus placebo (two trials including 43 participants (Gibson 2003; Wiesemann 1998))
Primary outcome (1) Eradication of P. aeruginosa from the lower respiratory tract as defined by: (a) Clearance of P. aeruginosa from BAL, sputum or oropharyngeal cultures at 1, 2, 3, 6, 12 and 24 months after commencement of therapy We did not combine these two trials in a formal analysis of this outcome, as results were not available for all the participants in the Wiesemann trial, thereby precluding an intention-to-treat analysis. An available case analysis of the data presented in the Wiesemann trial showed that, when combined with the data from the Gibson trial, there was a reduction in the odds of a positive culture in the treatment group compared to the placebo group at one month, odds ratio (OR) 0.06 (95% confidence interval (CI) 0.01 to 0.33); and two months, OR 0.15 (95% CI 0.03 to 0.65) (Gibson 2003; Wiesemann 1998) . A sensitivity analysis following imputation of the missing data to provide best case and worst case scenarios for the combined analysis showed a range of possible results. The best case scenario showed a reduction in the odds of a positive culture of P. aeruginosa in the treatment group at both one month, OR 0.06 (95% CI 0.01 to 0.30); and two months, OR 0.14 (95% CI 0.03 to 0.60). In the worst case scenario the odds of a positive culture was reduced at one month, OR 0.08 (95% CI 0.02 to 0.38); but was not statistically significant at two months, OR 0.18 (95% CI 0.04 to 0.73). Wiesemann was able to demonstrate a statistically significant reduction in the odds of a positive culture from the lower respiratory tract specimen after six months, OR 0.06 (95%CI 0.00 to 0.92); and twelve months of treatment, OR 0.02 (95 % CI 0.00 to 0.67) (Wiesemann 1998).
(b) Time to next isolation of P. aeruginosa from BAL, sputum or oropharyngeal cultures Neither trial assessed or reported on this outcome.
(c) Time to chronic infection (defined as the presence of P. aeruginosa in each monthly sputum sample for six consecutive months or the presence of precipitating antibodies to P. aeruginosa or both) Neither trial assessed or reported on this outcome.
Secondary Outcomes (2) Mortality
Mortality was not included as an outcome in either trial. There were no reported deaths during any of the trial periods.
(3) QOL assessment
Neither trial assessed or reported on this outcome.
(4) Spirometric lung function
Wiesemann reported no change in spirometric pulmonary function during or after the treatment period, but no data were given (Wiesemann 1998). Gibson did not assess or report on spirometric lung function (Gibson 2003).
(5) Growth and nutritional status
The trial by Gibson was the only one to present data on weight (Gibson 2003). They found no significant difference between the two groups in the change in weight from baseline (measured at trial entry) and subsequent weights measured at one month, WMD 0.20 (95% CI -0.28 to 0.68) and two months, WMD 0.10 (95% CI -0.38 to 0.58).
(6) Frequency of respiratory exacerbations
(7) Isolation of other micro-organisms
Gibson reported no changes in the prevalence of other micro-organisms, including multi-resistant organisms, cultured from respiratory secretions (Gibson 2003). Wiesemann did not collect data on this outcome (Wiesemann 1998).
(8) Adverse effects to antibiotics
Gibson reported cough in association with inhalation in 7 out of 8 participants in the treatment group and in 12 out of 13 in the placebo group, OR 0.58 (95% CI 0.03 to 10.86) (Gibson 2003) . There was no evidence of a difference in serum creatinine levels or auditory threshold between the groups, however the numbers of participants was small (Gibson 2003) . Wiesemann reported one withdrawal from the placebo group because of cough, however the authors did not report on the presence or absence of cough in other participants (Wiesemann 1998).
Additional outcomes which have arisen during the review (9) Time to chronic infection (defined as the presence of P. aeruginosa in each monthly sputum sample for six consecutive months or the presence of precipitating antibodies to P. aeruginosa or both)
(10) Clinical and radiological scores
Only the Gibson trial reported modified Shwachmann scores (Gibson 2003) . These were recorded at one month and two months from enrolment and were expressed as both mean scores with standard deviations and mean change from baseline with standard deviations. There was no significant differences between the two groups in changes in either mean scores or modified Schwachman scores from baseline at either one month, WMD 1.30 (95% CI -2.36 to 4.96) or two months, WMD 3.80 (95% CI -0.22 to 7.82) (Gibson 2003).
Ciprofloxacin and colistin versus control (one trial including 26 participants (Valerius 1991)).
Primary outcome (1) Eradication of P. aeruginosa from the lower respiratory tract as defined by:
(a) No isolation of P. aeruginosa from BAL, sputum or oropharyngeal cultures at 1, 2, 3, 6, 12 and 24 months after commencement of therapy The included trial did not report on this outcome.
(b) Time to next isolation of P. aeruginosa from BAL, sputum or oropharyngeal cultures The included trial did not report on this outcome.
Secondary Outcomes (2) Mortality
The included trial did not report on this outcome.
(3) Quality of life
(4) Spirometric lung function
(5) Growth and nutritional status
(6) Frequency of respiratory exacerbations
(7) Isolation of other micro-organisms
(8) Adverse effects to antibiotics
Valerius did not describe cough specifically but reported that there were no adverse effects in either group (Valerius 1991).
Additional outcomes which have arisen during the review (9) Time to chronic infection (defined as the presence of P. aeruginosa in each monthly sputum sample for six consecutive months or the presence of precipitating antibodies to P. aeruginosa or both)
In the Valerius trial, from the data provided, it was possible to calculate the proportion of participants in each group who were defined as chronically colonised with P. aeruginosa from respiratory secretions at 3, 6, 12 and 24 month time points (Valerius 1991). The odds of being chronically infected with P. aeruginosa was reduced in the treatment group compared to the placebo group after 24 months, OR 0.12 (95% CI 0.02 to 0.79). No significant difference was detected between the two groups at the other time points. No other trials used this outcome measure to express their findings.
(10) Clinical and radiological scores
D I S C U S S I O N
Our review includes three trials of antibiotic strategies for the eradication of P. aeruginosa infection in CF, with data from 69 participants. The quality of the trials was variable with important deficiencies identified in each trial. An early interim analysis was performed due to slow accrual in one trial (Gibson 2003) . This trial was stopped early because of evidence of significant treatment effect. It has been suggested that the results of randomised controlled trials stopped early for benefit should be interpreted with caution particularly when the number of events is small (Montori 2005).
Cumulative data from 43 participants in two of the three included trials indicate that P. aeruginosa was more frequently eradicated from the respiratory secretions in the participants receiving antibiotics than from those receiving placebo (Gibson 2003; Wiesemann 1998) . This reduction in the number of isolates of P. aeruginosa was noted at both one month and two months, after the start of treatment. The accuracy of the analysis was hampered by incomplete follow-up of a number of participants in one of the trials. The absence of these data has complicated the combined analysis of the two trials that compare inhaled tobramycin with placebo; one trial was analysed on an intention to treat basis and another on an available case basis with a sensitivity analysis. A sensitivity analysis based on best and worst case scenarios demonstrated similar results to the available case analysis. The available case analysis revealed a reduction in the odds of a positive culture for P. aeruginosa in the group treated with tobramycin inhalation when compared to the odds in the placebo group at both one and two months from the start of treatment. The trial by Valerius suggests that the onset of chronic infection with P. aeruginosa, is delayed in those individuals who have received antibiotic therapy compared to those receiving no therapy (Valerius 1991). There was some evidence from the trials by Valerius and Wiesemann that this effect may persist for up to 24 months (Valerius 1991; Wiesemann 1998). There was evidence for no difference in adverse events or the isolation of other micro-organisms associated with antibiotic treatment, aimed at eradicating P. aeruginosa from the respiratory tract. These results should be interpreted with caution for a number of reasons.
The relationship between the presence of P. aeruginosa in secretions from the upper respiratory tract and the isolation of P. aeruginosa from the lower respiratory tract is inconsistent. Reporting of the presence of organisms in respiratory secretions is difficult to standardise, dependent on the sampling methods used and on the number of samples taken. The trials included in this review used a heterogeneous mix of methods to sample respiratory secretions from both the lower and upper respiratory tracts. No two trials used the same methods and more than one method was used in two trials. There was no subgroup analysis based on sampling method in any of the trials, probably owing to relatively small numbers of participants in individual trials. Wiesemann used a combination of oropharyngeal swabs and sputum samples, whereas Gibson used oropharyngeal swabs and bronchoscopic bronchoalveolar lavage fluid (Gibson 2003; Wiesemann 1998) . Armstrong has shown that the results of oropharyngeal specimens are poorly predictive of the presence of organisms in the lower respiratory tract (Armstrong 1996) . Valerius relied on sputum samples which can be of poor quality in younger children (Valerius 1991) .
The aim of antibiotic therapy for early P. aeruginosa infection in CF should be both eradication of the micro-organism and improvement in (or slowing in the rate of decline of ) clinical parameters, whilst minimising adverse effects and the isolation of new micro-organisms. If P. aeruginosa is successfully eradicated, but there is no measurable clinical benefit then, either P. aeruginosa is less important than many clinicians believe it to be, or (which is more likely) current measures of clinical status are not sufficiently sensitive to small but important changes in the condition of an individual with CF.
There are differences in the type and dose of drug administered to the treatment groups in the two trials where nebulised tobramycin was compared to placebo. Wiesemann utilised tobramycin nebulised parenteral preparation (injectable solution) at a low dose (80 mg twice daily) for a long duration (12 months) (Wiesemann 1998); whereas Gibson used tobramycin solution for inhalation (TSI, TOBI) at a high dose (300 mg twice daily) for a short duration (28 days) (Gibson 2003) . This is a potential source of heterogeneity between the trials. It is of interest that significant heterogeneity was detected between the trials at the one month time point but this was not detected at the two month time point.
No deaths were reported during the trial periods. The participants were young children with CF and mortality is low in this group of individuals. Eradication of isolates of P. aeruginosa is easiest in people with CF with recent onset of P. aeruginosa infection of the respiratory tract, in particular in those who have non-mucoid isolates of P. aeruginosa as they seem particularly susceptible to antibiotic therapy. As onset of P. aeruginosa infection in people with CF is usually in mid-childhood these results should not be extrapolated to older individuals or those with established P. aeruginosa infection of the lower respiratory tract.
A U T H O R S ' C O N C L U S I O N S
Implications for practice
Significantly more children with CF show clearance of P. aeruginosa from their respiratory secretions two months after commencing antibiotic therapy aimed at eradication of the organism from their lower respiratory tract when compared to placebo. This effect may last for several months. This review has not established any improvement in clinical outcome measures following treatment. However, the small numbers of participants in the eligible trials mean that this review may have insufficient statistical power to detect changes in these clinical outcomes. There was no significant difference in the rate of common adverse effects nor in the isolation of micro-organisms other than P. aeruginosa.
We found that nebulised antibiotics (or a combination of nebulised and oral antibiotics) were better than no treatment in treating early infection with P.aeruginosa, which was eliminated in the majority of individuals. Eradication may be sustained in the short term. We were unable to determine whether there is an associated clinical benefit to people with CF. Overall, there is insufficient evidence from this review to state which antibiotic strategy should be used, for the eradication of early P. aeruginosa infection in CF.
Implications for research
There is an urgent need for well-designed and executed trials, which are specifically designed to examine the hypothesis: that antibiotic treatment of early P. aeruginosa infection will prevent or delay chronic infection, and result in appreciable clinical benefit to patients, without causing them harm. This requires welldesigned, multicentre, double-blind, randomised controlled trials enrolling adequate numbers of participants to ensure the trial has sufficient power. Eradication treatment is part of routine clinical practice in many CF centres and clinical trials comparing alternative eradication regimens may be preferable for pragmatic reasons. Consideration should be given to appropriate outcome measures particularly spirometric lung function and nutritional status and duration of follow up, Long-term follow-up trials with careful clinical and bacteriological surveillance are required.
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